Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis

British Journal of Ophthalmology

Volumn 87, Issue 10, 2003, Pages 1206-1211

  Kidd, Michael ^a   McKenzie, S H ^b   Steven, I ^b   Cooper, C ^a   Lanz, R ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS   (Australia)

^c Novartis Ophthalmics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; KETOTIFEN; LEVOCABASTINE; PLACEBO;

ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ARTICLE; AUSTRALIA; BURN; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE PAIN; EYELID DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; PHARYNGITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; REDUCTION; RHINITIS; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS; HUMANS; KETOTIFEN; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIPERIDINES; RECURRENCE; SEASONS; TREATMENT OUTCOME;

EID: 0141636517     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.10.1206     Document Type: Article

References (14)

1. Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1-20.
2. Abelson MB, George MA, Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy 1993;70:95-109.
3. Allansmith MR, Ross RN. Ocular allergy. Clin Allergy 1998;18:1-13.
4. Leonardi A. Pathophysiology of allergic conjunctivitis. Acta Ophthalmol Scand 1999;228(Suppl):21-23.
5. Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand 2000;230(Suppl):18-21.
6. Grant SM, Goa KL, Fitton A, et al. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990;40:412-48.
7. Blumenthal MN, Schwartz RH, Kaiser H. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis. Ocul Immunol Inflamm 2000;8:159-67.
8. Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05% a multicenter comparison in subjects with seasonal allergic conjunctivitis. Adv Ther 2000;17:94-102.
9. Giede C, Metzenauer P, Petzold U, et al. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000;16:153-63.
10. Abelson MB. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand 1999;228(Suppl):38-42.
11. Gomes PJ, Welch DL, Abelson MB. Evaluation of the efficacy and safety of ketotifen fumarate in the allergen challenge model [ARVO Abstract]. Invest Ophthalmol Vis Sci 2000;41:S926, [Abstract 4926.]
12. Abelson MB, Schaefer, K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993;38(Suppl):115-32.
13. Nabe M, Miyagawa H, Agrawal DK, et al. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Allergy Proc 1991;12:267-71.
14. Devillier P, Arnoux B, Lalau KC, et al. Inhibition of human and rabbit platelet activation by ketotifen. Fundam Clin Pharmacol 1990;4:1-9.